Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Randomized, Placebo-controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Lucassin (Terlipressin) (The REVERSE Study)

Next Previous
Trial Profile

A Multi-Center, Randomized, Placebo-controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Lucassin (Terlipressin) (The REVERSE Study)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Terlipressin (Primary)
  • Indications Hepatorenal syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms REVERSE
  • Sponsors Ikaria; Mallinckrodt plc

Most Recent Events

  • 14 Nov 2023 Results assessing Decision-Analytic Model to Project the Benefit of Terlipressin Treatment Among Patients with Alcohol-Related Cirrhosis and Hrs using using data from this study presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
  • 14 Nov 2023 Results of pooled subgroup analysis (n=598) assessing Improved Mean Arterial Pressure from Baseline to the End of Treatment with Terlipressin is Associated with Hepatorenal Syndrome Reversal presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
  • 14 Nov 2023 Results of pooled analysis from two trials (CONFIRM-NCT02770716 and REVERSE-NCT01143246), presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top